Mitochondrial damage in adipose tissue of untreated HIV-infected patients

AIDS

Volumn 25, Issue 2, 2011, Pages 165-170

  Garrabou, Glòria ^a   López, Sònia ^a   Morén, Constanza ^a   Martínez, Esteban ^b   Fontdevila, Joan ^c   Cardellach, Francesc ^a   Gatell, Josep Maria ^b   Miró, Òscar ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Infectious Diseases Department   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

adipose tissue; antiretroviral treatment; HIV; mitochondria; mitochondrial DNA; mitochondrial function dysfunction; mitochondrial toxicity

Indexed keywords

CITRATE SYNTHASE; CYTOCHROME C OXIDASE; LAMIVUDINE; MITOCHONDRIAL DNA; STAVUDINE; ZIDOVUDINE;

ADIPOSE TISSUE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA CONTENT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIPODYSTROPHY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT; TREATMENT DURATION; VIRUS LOAD;

ADIPOSE TISSUE; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS; SPAIN;

EID: 78650921142     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283423219     Document Type: Article

References (31)

1. Pilon AA, Lum JJ, Sanchez-Dardon J, Phenix BN, Douglas R, Badley AD. Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor. Antimicrob Agents Chemother 2002; 46:2687-2691.
2. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. JBiol Chem2000;275:41325-41332.
3. El Hadri K, Glorian M, Monsempes C, Dieudonné MN, Pecqu-ery R, Giudicelli Y, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem 2004; 279:15130-15141.
4. Caron M, Auclair M, Lagathu C, Lombès A, Walker UA, Korn-probst M, Capeau J. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18:2127-2136.
5. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koop-mans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 1998; 12:1735-1744.
6. Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, Choi J, et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother 2009; 63:1244-1250.
7. Falutz J. Therapy insight: body-shape changes and metabolic complications associated with HIV and highly active anti-retroviral therapy. Nat Clin Pract Endocrinol Metab 2007; 3:651-661.
8. Hazan U, Romero IA, Cancello R, Valente S, Perrin V, Mariot V, et al. Human adipose cells express CD4, CXCR4, and CCR5 receptors: a new target cell type for the immunodeficiency virus-1? FASEB J 2002; 16:1254-1256.
9. Munier S, Borjabad A, Lemaire M, Mariot V, Hazan U. In vitro infection of human primary adipose cells with HIV-1: a reassessment. AIDS 2003; 17:2537-2539.
10. Giralt M, Doming P, Guallar JP, Rodriguez de la Concepción ML, Alegre M, Domingo JC, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/ HAART-associated lipodystrophy. Antivir Ther 2006; 11:729-740.
11. Caron-Debarle M, Lagathu C, Boccara C, Vigoroux C, Capeau J. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 2010; 16:218-229.
12. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 2009; 10:79-87.
13. Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-820.
14. Miró O, López S, Mart́nez E, Pedrol E, Milinkovic A, Deig E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004; 39:710-716.
15. Chiappini F, Teicher E, Saffroy R, Pham P, Falissard B, Barrier A, et al. Prospective evaluation of blood concentration of mito-chondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. Lab Invest 2004; 84:908-914.
16. Shikuma CM, Gerschenson M, Chow D, Libutti DE, Willis JH, Murray J, et al. Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status. AIDS Res Hum Retro-viruses 2008; 24:1255-1262.
17. McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23.
18. McComsey GA, Libutti DE, O'Riordan M, Shelton JM, Storer N, Ganz J, et al. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther 2008; 13:715-722.
19. Buffet M, Schwarzinger M, Amellal B, Gourlain K, Bui P, Prévot M, et al. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol 2005; 33:60-64.
20. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15:1801-1809.
21. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15: 1389-1398.
22. Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010; 51:591-599.
23. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, Wesse-lingh SL. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. Acquir Immune Defic Syndr 2002; 30:271-277.
24. Hammond E, Nolan D, James I, Metcalf C, Mallal S. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 2004; 18:815-817.
25. Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther 2003; 8:323-331.
26. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
27. Kim MJ, Leclercq P, Lanoy E, Cervera P, Antuna-Puente B, Maachi M, et al. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir Ther 2007; 12:1273-1283.
28. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, et al. Incidence of and risk factors for lipody-strophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48-56.
29. Mallon PWG, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971-979.
30. Dube MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, et al. Long-term body fat outcomes in antiretro-viral-näve participants randomized to nelfinavir or efevirenz or both plus dual nucleosides. J Acquir Immune Defic Syndr 2007; 45:508-514.
31. Miró O, López S, Rodŕguez de la Concepción M, Mart́nez E, Pedrol E, Garrabou G, et al. Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine. J Acquir Immune Defic Syndr 2004; 37:1550-1555.